liraglutide
AssetPeptideAlso 4P-004, 4P004, Liraglutide 6 MG/ML Pen Injector, Insulin Degludec/liraglutide Injection
GLP-1 receptor agonist that enhances glucose-dependent insulin secretion.
- Stage
- Approved
- Modality
- Peptide
- Target
- AMPK signalling
- Indications
- 15
- Trials
- 257
- Developers
- 7
Indications
15Cardiovascular disease
Approvedaccessdata.fda.gov7 Oct 2026
Cardiovascular events
Approvedema.europa.eu7 Oct 2026
Comorbidity
Approvedema.europa.eu7 Oct 2026
12 more
- Targets and what it contains6
- Owner and partners7
- Trials257
- Evidence for its targets7
- Competitors12
- Aging relevance2
- Signals5
Every asset’s record: target, stage, trials and the evidence behind it.
See ProUpdated 7 Oct 2026 · 25 sources